Why the study?
Does a prognostic model-based decision rule improve risk stratification and cost-effectiveness for resuming OAC therapy in patients with a first unprovoked VTE compared to standard strategies?
Does a prognostic model-based decision rule improve risk stratification and cost-effectiveness for resuming OAC therapy in patients with a first unprovoked VTE compared to standard strategies?
A post D-dimer prognostic model provides good discrimination for predicting VTE recurrence and may be cost-effective for guiding the resumption of oral anticoagulation in patients with a predicted annual risk >8%.
No takes yet. Share an insight, caveat, or question.
May support model-guided OAC resumption above 8% annual recurrence risk; extends systematic validation of post-D-dimer prediction in unprovoked VTE.
Ensor et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: